NCT05455671Completed
Real-Time Assessment of Lung Structure and Function in Children and Young Adults With CF Using Electrical Impedance Tomography
Source: ClinicalTrials.gov · Last updated 13 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to determine the ability of electrical impedance tomography (EIT) to identify structural and functional physiological changes that occur with disease progression in cystic fibrosis patients. The investigators also aim to determine whether EIT can serve as an alternative for CT to identify regions of air trapping and consolidation, whether EIT can provide clinically useful information about response to treatment for an acute PE, and whether EIT can provide longitudinal information about structural changes in the lung.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 48 (actual)
- First submitted
- 6 Jun 2022
- Start date
- 1 Aug 2022
- Primary completion date
- 20 Aug 2024
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Cystic fibrosis
- NCT number
- NCT05455671
What you commit to
- Study type: Observational
- Participants enrolled: 48
- From 1 Aug 2022 to the primary completion date, 20 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Wearing a pacemaker or a metallic surgical implant in the chest
Other illness
- Known congenital heart disease, arrhythmia, or history of heart failure
- History of infection with Burkholderia cepacia
Other
- Unwilling/refusal to sign consent
- Developmental delays that could result in an inability to complete study procedures
Who the study is looking for
- Cohort 1:
- Age 3-21 years
- Male or female
- Healthy subjects with no known or suspected chronic or temporary lung disease
- Cohort 2:
- Age 3-21 years
- Male or female
- CF as diagnosed based on sweat chloride value(\>60 mmol/L) or two known disease causing mutations
- Cohort 3:
- Age 3-21 years
- Male or female
- CF as diagnosed based on sweat chloride value (\>60 mmol/L) or two known disease causing mutations
- Experiencing a protocol defined pulmonary exacerbation and being started on oral or intravenous antibiotics
Age in the registry: 3 years to 21 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Hospital Colorado Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.